ATE475716T1 - Zusammenstellungen zur behandlung von neurodegenerativen erkrankungen - Google Patents

Zusammenstellungen zur behandlung von neurodegenerativen erkrankungen

Info

Publication number
ATE475716T1
ATE475716T1 AT02760784T AT02760784T ATE475716T1 AT E475716 T1 ATE475716 T1 AT E475716T1 AT 02760784 T AT02760784 T AT 02760784T AT 02760784 T AT02760784 T AT 02760784T AT E475716 T1 ATE475716 T1 AT E475716T1
Authority
AT
Austria
Prior art keywords
compositions
treatment
neurodegenerative diseases
subjects
methods
Prior art date
Application number
AT02760784T
Other languages
English (en)
Inventor
Keiya Ozawa
Shin-Ichi Muramatsu
Kunihiko Ikeguchi
Imaharu Nakamo
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23226283&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE475716(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Application granted granted Critical
Publication of ATE475716T1 publication Critical patent/ATE475716T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT02760784T 2001-08-29 2002-08-29 Zusammenstellungen zur behandlung von neurodegenerativen erkrankungen ATE475716T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31583801P 2001-08-29 2001-08-29
PCT/JP2002/008761 WO2003018821A2 (en) 2001-08-29 2002-08-29 Compositions and methods for treating neurodegenerative diseases

Publications (1)

Publication Number Publication Date
ATE475716T1 true ATE475716T1 (de) 2010-08-15

Family

ID=23226283

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02760784T ATE475716T1 (de) 2001-08-29 2002-08-29 Zusammenstellungen zur behandlung von neurodegenerativen erkrankungen

Country Status (10)

Country Link
US (1) US20030050273A1 (de)
EP (1) EP1421199B1 (de)
JP (1) JP4279141B2 (de)
KR (1) KR20040039316A (de)
CN (1) CN1304581C (de)
AT (1) ATE475716T1 (de)
AU (1) AU2002326163B2 (de)
CA (1) CA2457057C (de)
DE (1) DE60237158D1 (de)
WO (1) WO2003018821A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6815431B2 (en) 1998-04-15 2004-11-09 Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
AU2002359786A1 (en) * 2001-12-19 2003-07-09 Hiroaki Mizukami Adeno-associated virus-mediated delivery of gdnf to skeletal muscles
US6998118B2 (en) * 2001-12-21 2006-02-14 The Salk Institute For Biological Studies Targeted retrograde gene delivery for neuronal protection
WO2003055983A2 (en) * 2001-12-21 2003-07-10 The Salk Institute For Biological Studies Targeted retrograde gene delivery to motor neurons
US20060258576A1 (en) * 2003-09-05 2006-11-16 Licentia, Ltd Gdnf-related neuropeptides
JP2007509109A (ja) 2003-10-20 2007-04-12 エヌエスジーン・アクティーゼルスカブ パーキンソン病のインビボ遺伝子治療
WO2005074605A2 (en) * 2004-02-03 2005-08-18 University Of Rochester Recombinant molecular products for expression of heme oxygenase-1, heme oxygenase-2, and/or biliverdin reductase for treatment of neurodegenerative diseases or disorders
EP1769718B1 (de) 2004-07-02 2011-09-07 Osaka University Endoskopbefestigung und endoskop
EP3058959B1 (de) * 2005-05-02 2019-01-30 Genzyme Corporation Gentherapie für neurometabolische erkrankungen
CA2606490C (en) 2005-05-02 2018-02-06 Genzyme Corporation Gene therapy for spinal cord disorders
EP2389191A2 (de) 2009-01-23 2011-11-30 NsGene A/S Expression von neuropeptiden in säugetierzellen
CN102369024A (zh) * 2009-01-29 2012-03-07 加利福尼亚大学董事会 用于向整个皮质中分布高水平治疗剂以治疗神经障碍的方法
RU2603740C2 (ru) * 2009-05-02 2016-11-27 Джензим Корпорейшн Генная терапия нейродегенеративных нарушений
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
EP2634253B1 (de) 2010-10-27 2016-05-11 Jichi Medical University Adeno-assoziierte virus-virionen zur übertragung von genen in nervenzellen
CN102618507B (zh) * 2012-03-23 2015-04-22 首都医科大学 增加腺相关病毒靶向转导效率的重组腺相关病毒及其应用
US8999927B2 (en) 2012-04-02 2015-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Glial cell line-derived neurotrophic factor (GDNF) compositions and use thereof
US10076384B2 (en) 2013-03-08 2018-09-18 Symple Surgical, Inc. Balloon catheter apparatus with microwave emitter
CN107073051B (zh) 2014-10-21 2021-08-24 马萨诸塞大学 重组aav变体及其用途
JP2019530463A (ja) 2016-10-13 2019-10-24 ユニバーシティ オブ マサチューセッツ Ａａｖカプシド設計
US20230190958A1 (en) 2017-01-13 2023-06-22 Jichi Medical University AAV Vector for Disrupting Coagulation Factor-Related Gene on Liver Genome
EP3744846A4 (de) 2018-01-26 2021-11-17 Tokushima University Adeno-assoziiertes virus-virion zur behandlung von morbus tay-sachs und morbus sandhoff
CN110499330A (zh) * 2018-05-16 2019-11-26 上海市同济医院 重组腺相关病毒载体及其应用
WO2020026968A1 (ja) 2018-07-30 2020-02-06 株式会社遺伝子治療研究所 Ａａｖベクターによる遺伝子発現を増強する方法
WO2021009805A1 (ja) 2019-07-12 2021-01-21 株式会社遺伝子治療研究所 ヒト肝臓への遺伝子導入のためのアデノ随伴ウイルスビリオン
JPWO2022224372A1 (de) 2021-04-21 2022-10-27
WO2023093905A1 (zh) * 2021-11-29 2023-06-01 上海瑞宏迪医药有限公司 Aadc、gdnf多核苷酸及其用于治疗帕金森病

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
EP1243652A3 (de) * 1991-09-20 2003-03-26 Amgen Inc., Glial neurotropher Faktor
WO1995005864A1 (en) * 1993-08-27 1995-03-02 Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Convection-enhanced drug delivery
ATE386131T1 (de) * 1994-04-13 2008-03-15 Univ Rockefeller Aav-vermittelte überbringung von dna in zellen des nervensystems
US5929041A (en) * 1996-02-23 1999-07-27 Amgen Inc. Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
IL126626A0 (en) * 1996-05-03 1999-08-17 Abbott Lab Novel antiangiogenic peptides polynucleotides encoding same and methods for inhibiting angiogenesis
DE69941100D1 (de) * 1998-05-27 2009-08-20 Genzyme Corp AAV Vektoren zur Herstellung der Medikamente zur konvektion-erhöhten Verabreichung
CN1228995A (zh) * 1999-01-26 1999-09-22 卢杲 一种治疗老年性痴呆症、帕金森症、心脑血管病的药物
US6800281B2 (en) * 2000-11-09 2004-10-05 Oxford Biomedica (Uk) Limited Lentiviral-mediated growth factor gene therapy for neurodegenerative diseases

Also Published As

Publication number Publication date
CN1575340A (zh) 2005-02-02
EP1421199B1 (de) 2010-07-28
US20030050273A1 (en) 2003-03-13
DE60237158D1 (de) 2010-09-09
CA2457057A1 (en) 2003-03-06
CA2457057C (en) 2011-05-10
KR20040039316A (ko) 2004-05-10
CN1304581C (zh) 2007-03-14
AU2002326163B2 (en) 2007-10-25
WO2003018821A2 (en) 2003-03-06
JP4279141B2 (ja) 2009-06-17
EP1421199A2 (de) 2004-05-26
JP2005501127A (ja) 2005-01-13
WO2003018821A3 (en) 2003-10-30

Similar Documents

Publication Publication Date Title
DE60237158D1 (de) Zusammenstellungen zur behandlung von neurodegenerativen erkrankungen
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
NO20053855L (no) 1-fenylalkankarboksylsyrederivater til behandling av neurodegenerative sykdommer.
NO974767D0 (no) Anvendelse av glianeurotrof faktor (GDNF) til behandling av hörselssykdommer
ATE450269T1 (de) Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
ATE451929T1 (de) Von casein abgeleitete peptide und deren anwendung für die therapie
WO2005081628A3 (en) Casein derived peptides and therapeutic uses thereof
EA200901299A1 (ru) Композиции олигогулуроната и олигогалактуроната
BR112014016557A8 (pt) métodos de tratamento de sintomas comportamentais de distúrbios neurológicos e mentais
NZ515964A (en) A method for the prophylaxis and/or treatment of medical disorders
HRP20010877B1 (en) Composition for prevention and treatment of amyloidogenic disease
ATE477811T1 (de) Oxytocin zur behandlung von autismus und asperger-syndrom
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
WO2007132292A3 (en) Therapy for alzheimer's disease
ATE392208T1 (de) Zusammensetzungen zur prävention und behandlung von erkältung und grippe-ähnlichen symptomen, die cheliertes zink enthalten
WO2007035722A8 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
DE102005055128A1 (de) Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor
DE69819488D1 (de) Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
DE602005020178D1 (de) 5,6,7-trihydroxyheptansäure und analoge zur behandlung von augenkrankheiten und mit hyperproliferativen und angiogenen reaktionen verbundenen krankheiten
WO2007134118A3 (en) Protein based composition and methods of using same
DE60027127D1 (de) Verwendung von Polyaminosäurederivaten zur Behandlung von Seborrhoe und verwandten Hautstörungen
DE60129606D1 (de) Mittel und verfahren zur vorbeugung von durch chemotherapie ausgelöster alopezie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties